Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 23;5(1):vdad054. doi: 10.1093/noajnl/vdad054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Best percentage change in target PN volume from baseline as of cycle 13 day 1. No efficacy data were collected after cycle 13 day 1. Two patients were classified as PD: Best reduction in target PN volume was 37.9% for one of these patients (best response was PD due to PD in a non-target PN) and was a volume increase of 28.3% for the other. One patient was assessed as having PD due to progression in a non-target PN at cycle 5 day 1 and cycle 9 day 1, despite a >20% reduction in target PN volume from baseline at all time points. Reference lines represent ± 20% change in target PN volume, which represent PD and PR, respectively. PD, progressive disease; PN, plexiform neurofibroma; PR, partial response.